

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

19 October 2023 (19.10.2023)



(10) International Publication Number

WO 2023/200842 A1

(51) International Patent Classification:

A61P 35/00 (2006.01) A61K 47/18 (2017.01)

A61K 47/02 (2006.01) A61K 38/00 (2006.01)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(21) International Application Number:

PCT/US2023/018289

(22) International Filing Date:

12 April 2023 (12.04.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/330,553 13 April 2022 (13.04.2022) US

(71) Applicant: EXOXEMIS, INC. [US/US]; P.O. Box 7570, Little Rock, Arkansas 72217 (US).

(72) Inventors: ALLEN, Robert C.; P.O. Box 7570, Little Rock, Arkansas 72217 (US). STEPHENS JR, Jackson T.; P.O. Box 7570, Little Rock, Arkansas 72217 (US).

(74) Agent: ATKINSON, Mary E. et al.; 925 4th Ave., Suite 2900, Seattle, Washington 98104 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(54) Title: COMPOSITIONS AND METHODS FOR TREATING SOLID CANCER

(57) Abstract: Compositions and methods for treating solid cancer are provided. Specifically, the disclosure provides compositions comprising haloperoxidases, and methods comprising administering such compositions, for treating solid cancer.

WO 2023/200842 A1

COMPOSITIONS AND METHODS FOR TREATING SOLID CANCER

BACKGROUND

[0001] The present disclosure generally relates to compositions and methods for treating solid cancer. Specifically, the disclosure provides compositions comprising haloperoxidases, and methods of using such compositions for treating solid cancer.

[0002] There is no doubt that cancer is and will remain a major impact on society, globally. According to the current statistics produced by the United States National Institutes of Health, in 2020, an estimated 1,806,590 new cases of cancer will be diagnosed in the United States and 606,520 people will die from the disease (<https://www.cancer.gov/about-cancer/understanding/statistics>).

[0003] Cancer is a disease that is characterized by uncontrolled cell growth, almost anywhere in the body. Tumor formation is where uncontrolled cell growth occurs in solid tissue such as an organ, muscle, or bone. To this point, a large portion of the most common cancers are solid, tumor-forming cancers such as breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, kidney and renal pelvis cancer, endometrial cancer, cervical cancer, pancreatic cancer, thyroid cancer, and liver cancer. Solid cancers include sarcomas, carcinomas, and lymphomas.

[0004] While rates of cancer survival are increasing through the development of improved therapies, the cancer mortality rate remains high - 158.3 deaths per 100,000 men and women per year in the United States (based on 2013–2017 deaths). Improved cancer therapies are therefore the subject of ongoing research and development by the scientific community.

[0005] For most solid cancers, abnormal tissue is biopsied for diagnosis. Surgery to remove as much of a tumor as possible, (commonly referred to as debulking), may be a therapeutic option. Debulking may also increase the effectiveness of subsequently administered anticancer therapies, such as immunotherapy, chemotherapy and/or radiotherapy. However, surgical intervention in cancer therapy (whether by biopsy or debulking) is not without risk. In addition to reproducing uncontrollably, cancer cells lose cohesiveness and organization of normal tissue, and may detach from a primary tumor during biopsy or surgery to travel elsewhere in the body via the circulatory and lymphatic systems. Cancer spread (i.e. metastases) during biopsy or surgical intervention therefore presents a significant risk to a cancer patient.

[0006] Some solid cancers, such as bladder, brain or spinal cord cancer, are difficult to biopsy and/or treat (surgically or non-surgically) through inaccessibility to the site of cancer growth. Accordingly, such cancers may result in high incidences of patient mortality.

[0007] There is a need to minimize solid cancer metastasis during biopsy or surgery, and/or to improve treatment of 'hard-to-reach' solid cancers.

[0008] There is a particular need for new therapeutics in the management of non-muscle invasive bladder cancer (NMIBC). Current protocols for the management of NMIBC routinely involve endoscopic resection of the tumor followed by intravesical treatment with cytotoxic chemotherapy agents (e.g. Gemcitabine, Mitomycin, Docetaxel) or BCG (Bacillus Calmette-Guerin), which acts as an activator of a local immune response. Requisite to the activity of these agents is the direct surface contact between the treating agent and residual cancer cells. Several shortcomings of these treatments exist, however, including limitations in efficacy as manifested by relatively high recurrence rates, non-selective mechanisms of action, which can result in cytotoxicity towards normal epithelium and associated morbidity, and potential for systemic side effects. Moreover, due to special handling requirements of these agents, administration is generally performed in a clinical setting, and requires repeated clinic visits, leading to financial and other burdens on both the patient and clinic providers. These limitations highlight the need for new therapeutics in treatment of NMIBC that not only enhance therapeutic efficacy and diminish morbidity, but also have a safety profile that may potentially permit in-home administration.

[0009] Myeloperoxidase (MPO) is a cationic enzyme secreted by granulocytic leukocytes that has peroxidase and haloperoxidase activity, hence enabling the generation of highly reactive oxidants. In the presence of hydrogen peroxide (H_2O_2) and the halide chloride (Cl^-), MPO catalyzes the oxidation of chloride to generate highly reactive hypochlorous acid (OCl^-). Hypochlorous acid can react with a second H_2O_2 generating electronically excited singlet molecular oxygen ($^1\text{O}_2^*$). Both OCl^- and $^1\text{O}_2^*$ have significant cytotoxic activity (with no free radical activity involved). Appeal for the use of MPO as an antineoplastic agent in bladder cancer lies primarily in its selective binding ability and its topical mechanism of action. Because of its cationic surface properties, MPO has a strong affinity for targets with anionic features, such as has been demonstrated for bladder cancer cells. The ability of MPO to avidly and selectively bind bladder cancer cells, again due to their anionic surface profile, coupled with the millisecond half-life of $^1\text{O}_2^*$, limits the "kill zone" to a small radius of less than a half micrometer, thus enabling

selective cytotoxic activity against bladder tumor cells to which the enzyme is bound while sparing normal adjacent urothelial epithelium, which have a more neutral electrostatic profile. Moreover, intravesical administration of MPO and associated reagents would pose minimal systemic toxicity due to the large molecular weight of MPO (144 kDa) and rapid inactivation within the circulation by catalase and the reticuloendothelial system

SUMMARY

[0010] This summary is provided to introduce a selection of concepts in a simplified form that are further described below in the Detailed Description. This summary is not intended to identify key features of the claimed subject matter, nor is it intended to be used as an aid in determining the scope of the claimed subject matter.

[0011] The present disclosure is predicated on the surprising and unexpected finding that haloperoxidase-containing compositions, including myeloperoxidase compositions, exhibit anticancer properties and have a less toxic effect on normal cells.

[0012] According to one aspect of the disclosure, there is provided a method of treating a solid cancer in a patient, the method comprising administering to the patient an effective amount of a pharmaceutical composition comprising a haloperoxidase.

[0013] In another aspect, the disclosure provides a method of treating a solid cancer in a patient, the method comprising administering to the patient an effective amount of a composition comprising a haloperoxidase, a halide, a peroxide, or a peroxide-producing oxidase and a substrate for the oxidase, and a pharmaceutically acceptable carrier.

[0014] In another aspect, the disclosure provides a method of treating a solid cancer in a patient, the method comprising administering to the patient an effective amount of a composition comprising a haloperoxidase, a halide, a peroxide, or a peroxide-producing oxidase and a substrate for the oxidase, one or more amino acids, and a pharmaceutically acceptable carrier.

[0015] In another aspect, the disclosure provides a method of treating a solid cancer in a patient, the method comprising administering to the patient an effective amount of a first composition comprising a haloperoxidase, a halide, one or more amino acids, and a pharmaceutically acceptable carrier, and a second composition comprising hydrogen peroxide. The first composition and the second composition can be administered concurrently or sequentially.

[0016] In another aspect, the disclosure provides a method of treating a solid cancer in a patient, the method comprising administering to the patient an effective amount of a

first composition comprising a haloperoxidase, a halide, one or more amino acids, a peroxide-producing oxidase, and a pharmaceutically acceptable carrier, and a second composition comprising a substrate for the peroxide-producing oxidase. The first composition and the second composition can be administered concurrently or sequentially.

[0017] In yet another aspect, the disclosure provides a composition for treating a solid cancer in a patient, the composition comprising a haloperoxidase, a halide, a peroxide, or a peroxide-producing oxidase and a substrate for the oxidase, and a pharmaceutically acceptable carrier.

[0018] In yet another aspect, the disclosure provides a composition for treating a solid cancer in a patient, the composition comprising a haloperoxidase, a halide, a peroxide, or a peroxide-producing oxidase and a substrate for the oxidase, one or more amino acids, and a pharmaceutically acceptable carrier.

[0019] In yet another aspect, the disclosure provides a composition for treating a solid cancer in a patient, the composition consisting essentially of a haloperoxidase, a halide, a peroxide, one or more amino acids, and a pharmaceutically acceptable carrier.

[0020] In yet another aspect, the disclosure provides a combination for treating a solid cancer in a patient, the combination comprising a haloperoxidase, a halide, a peroxide, one or more amino acids, and a pharmaceutically acceptable carrier.

[0021] In yet another aspect, the disclosure provides a combination for treating a solid cancer in a patient, the combination comprising a haloperoxidase, a halide, a peroxide-producing oxidase and a substrate for the oxidase, one or more amino acids, and a pharmaceutically acceptable carrier.

[0022] In yet another aspect, the disclosure provides a composition for treating a solid cancer in a patient, the composition comprising a haloperoxidase, and optionally one or more of a halide, ethanolamine, a peroxide, or a peroxide-producing oxidase and a substrate for the oxidase, or a pharmaceutically acceptable carrier.

[0023] In yet another aspect, the disclosure provides a composition for treating a solid cancer in a patient, the composition consisting essentially of a haloperoxidase, and optionally one or more of a halide, ethanolamine, a peroxide, or a peroxide-producing oxidase and a substrate for the oxidase, or a pharmaceutically acceptable carrier.

[0024] In embodiments, the haloperoxidase is selected from a group consisting of: myeloperoxidase (MPO), eosinophil peroxidase (EPO), lactoperoxidase (LPO), chloroperoxidase (CPO), functional derivatives thereof, and combinations thereof.

[0025] In some embodiments, the haloperoxidase is eosinophil peroxidase.

[0026] In some embodiments, the haloperoxidase is myeloperoxidase.

[0027] In embodiments, the haloperoxidase catalyzes halide oxidation and disproportionation of peroxide yielding singlet molecular oxygen resulting in one or more of: inhibition of cancer cell growth, inhibition of cancer cell metastases, or cancer cell death.

[0028] In embodiments, the solid cancer is selected from the group comprising: breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, kidney and renal pelvis cancer, endometrial cancer, cervical cancer, pancreatic cancer, thyroid cancer, liver cancer, brain cancer and spinal cord cancer.

[0029] In some embodiments, the solid cancer is bladder cancer.

[0030] Other embodiments of the invention will be evident from the following detailed description of various aspects of the invention.

DETAILED DESCRIPTION

Definitions

[0031] The terms “a,” “an,” “the” and similar referents used in the context of describing inventive concepts (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context.

[0032] All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context.

[0033] The use of any and all examples, or exemplary language (e.g., “such as”) provided herein is intended merely to provide better illumination and does not pose a limitation on the scope of the disclosure. No language in the specification should be construed as indicating any non-claimed element is essential.

[0034] Except where otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term ‘about’. Accordingly, unless

indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present disclosure. At the very least, each numerical parameter should be construed in light of the number of significant digits and ordinary rounding conventions. The term "about" may be understood to refer to a range of $\pm 10\%$, such as $\pm 5\%$ or $\pm 1\%$ or, $\pm 0.1\%$.

[0035] Recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. For example, if a range is from about 1 to about 50, it is deemed to include, for example, 1, 7, 34, 46.1, 23.7, or any other value or range within the range.

[0036] The terms "protein" and "polypeptide" are used interchangeability herein. The 3-letter code for amino acids as defined in conformity with the IUPAC-IUB Joint Commission on Biochemical Nomenclature is used throughout this disclosure. It is also understood that a polypeptide may be coded for by more than one nucleotide sequence due to the degeneracy of the genetic code.

[0037] Reference is made herein to "enzymes", such as haloperoxidase or glucose oxidase. In the present context, an enzyme is a protein/polypeptide which acts as a catalyst to bring about a specific biochemical reaction. Included within the scope of enzymes of the present disclosure include those isolated from a natural source having the unmodified amino acid sequence identical to that found in nature, as well as "functional derivatives" thereof.

[0038] The term "haloperoxidase" refers to an enzyme which catalyzes the hydrogen peroxide dependent oxidation of halide generating hypohalous acid; this hypohalous acid can react with an additional hydrogen peroxide to generate singlet molecular oxygen. A haloperoxidase according to the present disclosure may be also referred to as a halide:hydrogen peroxide oxidoreductase (e.g., EC No. 1.11.1.7 and EC No. 1.11.1.10 under the International Union of Biochemistry) for which halide, e.g., chloride or bromide, is the electron donor or reductant and peroxide is the electron receiver or oxidant. Suitable haloperoxidases, include myeloperoxidase (MPO), eosinophil peroxidase (EPO), lactoperoxidase (LPO), chloroperoxidase (CPO), functional derivatives thereof and combinations thereof. The haloperoxidase may be derived from any source, including human and non-human animals, or cell cultures.

[0039] A “derivative” of an enzyme of the disclosure generally retains the characteristic enzymatic activity observed in the wild-type, native or parent form to the extent that the derivative is effective for similar purposes as the wild-type, native or parent form.

[0040] The term “functional fragment” or “functional derivative” when used in the context of enzymes of the disclosure encompasses naturally occurring, synthetically or recombinantly produced nucleic acids or fragments and encode enzymes having the functional characteristics of the native, unmodified parent enzyme present disclosure. A “functional derivative” may include a “substituted variant” which is a variant in which at least one amino acid residue in a native sequence has been removed and inserted into the same position by a different amino acid. The substitution may be single, wherein only one amino acid in the molecule is substituted; or there may be multiple, wherein the same molecule has two or more amino acids substituted. Multiple substitutions can be located at successive sites. Likewise, an amino acid can be substituted with multiple residues, including substitutions and insertions. An “insertion variant” is a variant in which one or more amino acids are inserted into an amino acid immediately adjacent to a particular position in a native sequence. Immediately adjacent to the amino acid means attached via an alpha-carboxy or alpha-amino functional group of the amino acid. A “deleted variant” is a variant in which one or more amino acids in the native amino acid sequence are removed. Typically, a deleted variant has one or two amino acids deleted in a particular region of its molecule.

[0041] The term “isolated” or “purified” refers to a material that is removed from its original environment (e.g. the natural environment, if it is naturally occurring). For example, the material is the to be “purified” when it is present in a particular composition in a higher concentration than exists in a naturally occurring or wild type organism or in combination with components not normally present upon expression from a naturally occurring or wild type organism. For example, a naturally-occurring protein/polypeptide present in a living organism is not isolated, but the same protein/polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated. Such proteins/polypeptides could, for example, be part of a composition, and still be isolated in that such a composition is not part of the natural environment of the proteins/polypeptides.

[0042] The term “pharmaceutically acceptable” as used herein refers to substances that do not cause substantial adverse allergic or immunological reactions when administered to a patient. A “pharmaceutically acceptable carrier” includes, but is not

limited to, solvents, coatings, dispersion agents, wetting agents, isotonic and absorption delaying agents and disintegrants.

[0043] As used herein, "treat", "treating" or "treatment" of a disease, condition or disorder means accomplishing one or more of the following: (a) reducing the severity and/or duration; (b) limiting or preventing development of characteristic symptoms; (c) inhibiting worsening of symptoms; (d) limiting or preventing recurrence; and (e) limiting or preventing recurrence of symptoms. That is, the terms include both prophylactic or preventive treatment (that prevent and/or slow the development of a targeted pathologic disease, condition or disorder) and curative, therapeutic or disease-modifying treatment, including therapeutic measures that cure, slow down, lessen symptoms of, and/or halt progression of a disease, condition or disorder; and treatment of a patient at risk of contracting a disease or suspected to have contracted a disease, as well as a patient who is ill or has been diagnosed as suffering from a disease, condition or disorder. The terms do not necessarily imply that a patient is treated until total recovery. The terms may also refer to the maintenance and/or promotion of health in an individual not suffering from a disease but who may be susceptible to the development of an unhealthy condition. The terms may also include the potentiation or otherwise enhancement of one or more primary prophylactic or therapeutic measures. As non-limiting examples, a treatment can be performed by a patient, a caregiver, a doctor, a nurse, or another healthcare professional.

[0044] As used herein, "prevent", "preventing", "prevention", or "prophylaxis" of a disease or disorder means preventing that a disorder occurs in patient. "Prevention" includes reduction of risk, incidence and/or severity of a disease, condition or disorder.

[0045] As used herein, the expressions "is for administration" and "is to be administered" have the same meaning as "is prepared to be administered." In other words, the statement that an active compound "is for administration" has to be understood in that the active compound has been formulated and made up into doses so that the active compound is in a state capable of exerting its therapeutic activity.

[0046] The terms "effective amount" or "therapeutic amount" are intended to mean that amount of a substance that will elicit the desired biological or medical response of a tissue, a system, animal, or human. The term "prophylactically effective amount" is intended to mean that amount of a pharmaceutical drug that will prevent or reduce the risk of occurrence of the biological or medical event in a tissue, a system, animal, or human.

[0047] The terms "comprise", "comprises", "comprised" or "comprising", "including" or "having" and the like in the present specification and claims are used in an inclusive sense, that is to specify the presence of the stated features but not preclude the presence of additional or further features.

[0048] Specific embodiments disclosed herein may be further limited in the claims using "consisting of" or "consisting essentially of" language. When used in the claims, whether as filed or added per amendment, the transition term "consisting of" excludes any element, step, or ingredient not specified in the claims. The transition term "consisting essentially of" limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristic(s). Embodiments of the disclosure so claimed are inherently or expressly described and enabled herein.

Haloperoxidase-Containing Compositions

[0049] Haloperoxidases are widespread in nature, produced by mammals, algae, and fungi. US 6,294,168 discloses that haloperoxidases can be used as antimicrobial agents (effective particularly against bacteria and fungi), as they selectively bind to target microbes, and in the presence of peroxide and halide, inhibit target microbe growth. Use of low concentrations of haloperoxidase maximizes selective binding to target microbes, without eliminating desirable microbes, or causing significant damage to host cells. The selective nature of haloperoxidase binding makes them useful in therapeutic or prophylactic antimicrobial treatment of human or non-human patients.

[0050] The present disclosure is predicated on the surprising and unexpected finding that haloperoxidase-containing compositions exhibit anticancer properties. In one aspect, the disclosure provides methods for treating solid cancer by contacting the cancer with a composition comprising a haloperoxidase. In another aspect, the disclosure provides compositions for treating solid cancer, the compositions comprising a haloperoxidase. In yet another aspect, the disclosure provides a combination for treating a solid cancer, the combination comprising a haloperoxidase, and at least one of a halide, or a peroxide, or a peroxide-producing oxidase.

[0051] In some embodiments, the haloperoxidase catalyzes halide oxidation and disproportionation of peroxide to singlet molecular oxygen, treating the cancer by inhibiting cancer cell growth, metastases, or by cancer cell killing. In embodiments, suitable haloperoxidases according to the present disclosure include eosinophil peroxidase (EPO),

myeloperoxidase (MPO), lactoperoxidase (LPO), chloroperoxidase (CPO), functional derivatives thereof and combinations thereof.

[0052] In other embodiments, the method of treatment of the present disclosure further comprises administering an effective amount of peroxide or a peroxide-producing oxidase. A substrate for the oxidase may be optionally administered. Preferably, the peroxide-producing oxidase is glucose oxidase and the substrate is glucose. In further embodiments, the method further comprises administering the haloperoxidase with a halide, preferably a chloride or bromide.

[0053] In yet other embodiments, the haloperoxidase is administered in a first composition together with at least one further composition comprising one or more of: a halide, a peroxide, or a peroxide-producing oxidase plus a substrate for the peroxide-producing oxidase. Alternatively, the haloperoxidase may be formulated in a composition for administration, the composition also comprising one or more of a halide, a peroxide, or a peroxide-producing oxidase and a substrate for the peroxide-producing oxidase.

[0054] In yet other embodiments, the haloperoxidase is administered in a first composition together with at least one further composition comprising one or more of: a halide, ethanolamine, a peroxide, or a peroxide-producing oxidase plus a substrate for the peroxide-producing oxidase. Alternatively, the haloperoxidase may be formulated in a composition for administration, the composition also comprising one or more of a halide, ethanolamine, a peroxide, or a peroxide-producing oxidase and a substrate for the peroxide-producing oxidase. Alternatively, the haloperoxidase may be formulated in a composition for administration, the composition also comprising one or more of a halide, one or more amino acids, a peroxide, or a peroxide-producing oxidase and a substrate for the peroxide-producing oxidase.

[0055] In particular embodiments, eosinophil peroxidase (EPO) and myeloperoxidase (MPO) are preferred haloperoxidases for use in the present compositions, combinations and treatment methods. In further embodiments, MPO and EPO are porcine derived. Preferably, the purified haloperoxidases, porcine MPO and EPO, are those produced by Exoxemis, Inc.

[0056] The porcine MPO is preferably 98.9% pure by ultraperformance liquid chromatography (RP-UPLC) and 100% pure by molecular size exclusion high-performance liquid chromatography (SEC-HPLC). The guaiacol unit (GU) activity of the porcine MPO is preferably 404GU/mg; 1.0GU of activity consumes 1.0 μmol H_2O_2 /minute.

[0057] Porcine EPO is preferably 99.2% pure by reversed-phase high-performance liquid chromatography. The guaiacol unit (GU) activity of the porcine EPO is preferably 80GU/mg.

[0058] MPO and EPO are both cationic proteins. Without being bound by theory, it is believed that the cationic nature of such haloperoxidases makes them particularly adherent to the anionic surface of cancer cells. Thus, at a suitable pH, the electrostatic attraction and binding of the haloperoxidase to the anionic surface of cancer cells, with no or minimal binding to the surface of normal cells, results in selective binding of haloperoxidase to cancer cells, and in the presence of peroxide, the selective killing of cancer cells, with little or no damage to surrounding normal cells.

[0059] Haloperoxidases may differ in their physical properties and optimal conditions for enzymic activity (e.g. see US9782459). For example, MPO is around 150 kDa and is active at acidic pH (4.0 - 6.5), whereas EPO is around 70kDa and active at acidic to neutral pH (i.e. 5.0 - 7.4). In embodiments, compositions of the present disclosure may comprise a haloperoxidase where the characteristics of the haloperoxidase may be aligned with the conditions of the site of cancer treatment. In embodiments, the choice of haloperoxidase is determined by the pH at the site of treatment. In other embodiments, the choice of haloperoxidase is determined by accessibility to the site of treatment.

[0060] Effective amounts of haloperoxidase employed in the compositions, combinations or treatment methods of the disclosure may vary widely depending on conditions under which the compositions are employed, the environment of use and the desired result. In some embodiments, the compositions of the disclosure will comprise from about 1 to about 100,000 µg/ml of haloperoxidase, more preferably from about 5 to about 50,000 µg/ml, and even more preferably from about 10 to about 5,000 µg/ml haloperoxidase.

[0061] Peroxide-producing oxidases effective in the present disclosure include, for example, oxidases, such as glucose oxidase, cholesterol oxidase and galactose oxidase. As a representative example, when the oxidase is glucose oxidase and its substrate is glucose, the compositions of the present disclosure may comprise from about 0.05 to about 3,000 U/ml, more preferably from about 0.1 to about 1,000 U/ml, and even more preferably from about 1 to about 500 U/ml of glucose oxidase, and from about 0.1 to about 100 mM, more preferably from about 0.5 to about 80 mM, and even more preferably from about 1 to about 50 mM glucose. Preferably, the glucose oxidase as used in compositions of the present disclosure is derived from *Aspergillus Niger*. More preferably, the glucose

oxidase is that produced by Exoxemis, Inc, which is isolated from *Aspergillus niger*, purified to 99.8% by RP-HPLC and 99.9% by SECHPLC, and optionally, wherein the unit (U) activity of GO is 309 U/mg (in which 1.0U oxidizes 1.0 μ mol of β -D-glucose to D-gluconolactone and H_2O_2 /minute at pH 5.1 at 35°C.

[0062] As noted above, haloperoxidases useful in the compositions, combinations or treatment methods of the present disclosure, if not used in combination with a peroxide-producing oxidase, may be administered in combination with peroxide. Administration of peroxide, as with a peroxide-producing oxidase, may be simultaneous or sequentially to the administration of the haloperoxidase. In embodiments, peroxide may be administered to a site of treatment at a concentration including, but not limited to, about 1 μ M to about 100 mM, preferably about 1 mM to about 50 mM, more preferably about 9 mM. Administration may depend on accessibility to the site of treatment. In embodiments, a bolus of peroxide of between about 1 ml to 1000 ml, preferably 100 ml to 800 ml, most preferably 500 ml may be administered.

[0063] In some embodiments, the haloperoxidase may optionally be supplied to a site of treatment with at least two amino acids, or at least three amino acids, selected from the group comprising glycine, L-alanine, D-alanine, L-alanine anhydride, L-glutamine, L-glutamic acid, glycine anhydride, hippuric acid, L-histidine, L-leucine, D-leucine, L-isoleucine, D-isoleucine, L-lysine, L-ornithine, D-phenylalanine, L-phenylalanine, L-proline, L-hydroxyproline, L-serine, L-tyrosine, L-threonine, D-threonine, L-tyrosine, L-valine, D-valine, beta amino acids, such as beta alanine, L-beta-homoleucine, D-beta-homoleucine, 3-aminobutanoic acid, L-2,3-diaminopropionic acid monohydrochloride, D-2,3-diaminopropionic acid monohydrochloride, L-3-aminoisobutyric acid, D-3-aminoisobutyric acid, ethyl 3-aminobutyrate, sarcosine methyl ester hydrochloride and nipecotic acid, or an alkyl ester or pharmaceutically acceptable salt thereof. In a particular embodiment, the haloperoxidase may be formulated together with the amino acids, or alternatively the amino acids may be supplied as a separate composition for premixing before administration, or simultaneous or concurrent administration.

[0064] In some embodiments, the haloperoxidase may be supplied to a site of treatment with two amino acids, wherein the two amino acids are glycine and L-proline.

[0065] Effective amounts of the amino acids which may be optionally employed in the compositions/combinations of the disclosure will vary depending on the amount of haloperoxidase in the compositions/combinations and conditions present in the environment of use. In an example, the compositions may generally comprise from about

0.1 to about 500 mM, more preferably from about 0.2 to about 100 mM, and even more preferably from about 0.3 to about 50 mM of each of the amino acids of the disclosure.

[0066] The compositions/combinations of the present disclosure may optionally comprise a halide. When the halide is chloride, the amount of chloride used in the compositions of the present disclosure will preferably fall in the range of about 10 μ mol chloride to about 200 μ mol per ml of solution (i.e., 10 to 200 mEq chloride/L) chloride. The physiologic concentration of chloride in plasma is about 105 mEq/L. When included, the compositions of the present disclosure may comprise from about 0.5 μ mol bromide to about 20 μ mol bromide per ml (i.e., 0.5 to 20 mEq bromide/L) of liquid composition, more preferably from about 1 μ mol bromide to about 10 μ mol bromide per ml (i.e., 1 to 10 mEq bromide/L) of liquid composition, and most preferably from about 100 nmol bromide to about 1 μ mol bromide per ml of liquid composition. In some embodiments, the halide is sodium chloride.

[0067] The compositions/combinations of the present disclosure may optionally comprise ethanolamine.

[0068] The compositions/combinations may optionally comprise a pharmaceutically acceptable carrier. In some embodiments, the compositions may be conveniently provided in a liquid carrier. Any liquid carrier may be generally used for this purpose, provided that the carrier does not significantly interfere with the selective binding capabilities of the myeloperoxidase or with enzyme activity. Alternatively, the compositions may be provided in solid form with activation on solubilization in liquid.

[0069] In embodiments of compositions or combinations of the present disclosure that include a substrate for the peroxide-producing oxidase, the haloperoxidase lends itself to construction as a binary formulation in which the composition's active agents are formulated in two separate parts for consolidation at the time of use. For example, the first composition of the binary formulation may comprise a solution containing both the haloperoxidase and the peroxide-producing oxidase, and optionally a halide. In some embodiments, the first composition may optionally comprise two or three amino acids. In some embodiments, the two amino acids are glycine, and L-proline. In some embodiments, the three amino acids are glycine, L-alanine and L-proline. The second composition of the binary formulation may comprise a substrate for the oxidase, e.g., glucose (i.e., dextrose) in the case of glucose oxidase. The substrate may be provided, for example, in the form of a solid wafer. In some embodiments, the haloperoxidase

composition may additionally comprise alcohol in order to facilitate oxidase substrate solubilization and utilization by the oxidase.

[0070] In one embodiment, the methods of the present disclosure comprise administering to a site, prophylactically or therapeutically, a combination of compositions. For example, a first composition comprising haloperoxidase and a peroxide-producing oxidase may be administered. In some embodiments, the first composition further comprises two amino acids and a halide. A second composition comprising a substrate for the peroxide-producing oxidase may be administered separately. In some embodiments, a first composition comprising haloperoxidase, a halide, and two amino acids may be administered. A second composition comprising hydrogen peroxide may be administered separately. In some embodiments, the first composition and the second composition are mixed before administration to the site of infection. In some embodiments the first composition and the second composition are administered concurrently to the site. In some embodiments the first composition and the second composition are administered sequentially to the site. The first composition and the second composition may be administered in any order.

[0071] In one embodiment, the methods of the present disclosure comprise administering to a site, prophylactically or therapeutically, a combination of compositions. For example, a first composition comprising haloperoxidase, ethanolamine, and a halide may be administered. A second composition comprising hydrogen peroxide may be administered separately. In some embodiments, the first composition comprises a haloperoxidase, two amino acids, and a halide. In some embodiments, the first composition and the second composition are mixed before administration to the site of infection. In some embodiments the first composition and the second composition are administered concurrently to the site. In some embodiments the first composition and the second composition are administered sequentially to the site. The first composition and the second composition may be administered in any order.

[0072] As an illustrative example, a composition of the present disclosure suitable for use as anticancer treatment may comprise from about 1 to 50,000 µg/ml haloperoxidase, from 0.01 to 500 units of glucose oxidase, and optionally: from 0.1 to 500 µmol/mL (i.e., from 0.1 to 500 mM) of glycine, from 0.1 to 500 µmol/mL (i.e., from 0.1 to 500 mM) of D-isoleucine, from 0 to 100 µmol/mL (i.e., from 0 to 100 mM) of L-alanine, and from 50 to 500 mEq/L of chloride. The above composition may be combined with from 1 to 500 µmol/mL (i.e., from 1 to 500 mM) of glucose or dextrose.

[0073] As an illustrative example, a composition of the present disclosure suitable for use as anticancer treatment may comprise from about 1 to 50,000 µg/ml haloperoxidase, from 0.1 to 500 µmol/mL (i.e., from 0.1 to 500 mM) of glycine, from 0.1 to 500 µmol/mL (i.e., from 0.1 to 500 mM) of L-proline, from 50 to 500 mEq/L of chloride and from 1 mM to about 50 mM hydrogen peroxide.

[0074] As an illustrative example, a composition of the present disclosure suitable for use as an anticancer treatment may comprise eosinophil peroxidase, ethanolamine, sodium bromide and hydrogen peroxide. Such a composition may be suitable to treat bladder cancer.

[0075] As an illustrative example, a composition of the present disclosure suitable for use as an anticancer treatment may comprise myeloperoxidase (MPO), glycine, L-proline, sodium chloride (NaCl) and hydrogen peroxide (H₂O₂). An illustrative example of such a composition comprises 20nM MPO, 10mM H₂O₂, 100mM NaCl, 0.21mM glycine, and 0.21 mM L-proline. Such a composition may be suitable to treat bladder cancer.

Treatable Cancers

[0076] The cancers targeted by the present invention are solid cancers and include various cancers other than hematological cancers (malignant lymphoma, leukemia, multiple myeloma etc). Typical examples of a solid cancer include lung cancer, breast cancer, stomach cancer, liver cancer, colon cancer, tongue cancer, thyroid cancer, kidney cancer, prostate cancer, uterine cancer, cervical cancer, and ovary. Preferred specific examples of the solid cancer include, for example, bladder cancer, colon cancer, lung cancer, pancreatic cancer, kidney cancer, or breast cancer. A solid cancer may also include melanoma or glioma, but is not limited thereto.

[0077] In the context of non-surgical anticancer treatment, such as topical applications, anticancer compositions of the present disclosure can be administered in any effective pharmaceutically acceptable form to warm blooded animals, including human and non-human animal patients. In this context, compositions of the disclosure may be administered at any mucosal or epithelial surface. For example, the compositions of the disclosure may be administered in topical, lavage, oral, vaginal or rectal suppository dosage forms, as a topical, buccal, nasal spray, aerosol for inhalation or in any other manner effective.

[0078] For topical applications, the pharmaceutically acceptable carrier may take the form of liquids, creams, foams, lotions, ointments, suspensions, suppositories or gels, and

may additionally comprise aqueous or organic solvents, buffering agents, emulsifiers, gelling agents, moisturizers, stabilizers, surfactants, wetting agents, preservatives, time release agents, and minor amounts of humectants, sequestering agents, dyes, perfumes, and other components commonly employed in pharmaceutical compositions for topical administration. In addition, the compositions of the present disclosure may be impregnated in dressings or coverings for application to a patient.

[0079] In the context of more invasive anticancer treatment, such as tumor debulking (size reduction or elimination by excision) by surgery, anticancer compositions of the present disclosure may be administered extratumorally. For example, an extratumoral treatment may comprise applying to the surgical site, and/or an area surrounding a surgical site, a composition/combination of the present disclosure. In this context, haloperoxidase may be administered in solution or in any other dosage form, such as a subcutaneous injection or deposit.

[0080] In either non-surgical or surgical anticancer treatment using compositions, combinations or methods of the present disclosure, a patient in need may be treated with a further anticancer therapy, such as an immunotherapy, chemotherapy and/or radiotherapy. The further anticancer therapy may be administered to the patient prior, concurrently or post treatment with the compositions/combinations of the present disclosure.

[0081] Further examples of the invention are described below. However, it should be noted that the invention should not be limited to these examples, and that the invention is susceptible to variations, modifications and/or additions other than those specifically described, and it is to be understood that the invention includes all such variations, modifications and/or additions which fall within the scope of the claims.

EXAMPLES

Example 1 - *In vivo* tumor reduction activity of porcine eosinophil peroxidase (pEPO)

[0082] An experiment was performed to determine the tumor reduction activity of porcine eosinophil peroxidase (pEPO) in a mouse subcutaneous xenograft.

[0083] Tumor Cell Line Description: HT-1080 cells (Cat #CCL-121) purchased from American Type Culture Collection (ATCC) were used for the experiments. The cells were grown in complete media as described below. Cells were seeded in cell culture flasks and

incubated at 37°C in a fully-humidified atmosphere with 5% CO₂. Once the cells reached confluence, they were propagated and /or preserved as described below:

[0084] Cell Propagation and Preservation Procedure: performed according to standard methods:

- Subculturing Ratio: 1:4 to 1:8
- Medium Renewal: 2 to 3 times per week
- Propagation Procedure: Removed medium and washed twice with D-PBS (1X). Added 1X trypsin solution and allowed the flask to sit at room temperature (RT) or at 37°C until the cells detached. Added fresh medium, aspirated and dispense into new flasks. Record the number of passages.
- Preservation Procedure: Froze the cells in 95% complete growth medium supplemented by 5% DMSO. The first medium to be used after thawing the cells was Eagle's MEM that was supplemented by adequate concentrations of glucose (4500 mg/l D-glucose).
- Passaging Procedure: Removed medium and washed twice with D-PBS (1X). Added 1X trypsin solution and allowed the flask to sit at room temperature (RT) or at 37°C until the cells detached. Added fresh medium, aspirated and dispense into new flasks. Record the number of passages.
- Final Harvest Procedure: 6x T-150 flasks were harvested by removing the medium and washing once with 1X D-PBS. Added 1X trypsin solution and allowed flasks to sit at room temperature (RT) until cells detached. Quenched the trypsin using culture media (with bovine serum) and spun cells at 1000 rpm for 10 min. Washed twice with 1X D-PBS and resuspended the pellet in 1X D-PBS to a concentration of 52×10^6 cells/ml D-PBS.

[0085] HT-1080 cell line propagation, harvest and viability assessment was performed prior to injection into animals revealing the following: Total cell counts: 78×10^6 cells; Cell viability prior to injection: 98 %; Viable cells/mL: 51×10^6 viable cells/ml

[0086] Tumors: For the subcutaneous (SC) tumor growing model, a dose of 5.1×10^6 cells/mouse was injected SC into the right flank of each mouse in a 100 µl volume on study day 1. Tumor growth was followed twice a week by caliper measurements to determine the three parameters of length, width and height. Tumor volume was calculated according to the formula for an ellipsoid: $\frac{4}{3} \pi \times (La/2) \times (Wa/2) \times (Ha/2)$. La, Wa, and Ha, are the length, width and height of the tumor measured *in vivo* minus the skin thickness. Bi-fold

skin thickness was subtracted from the length and width parameters and single fold skin thickness was subtracted from the height measurement to determine La, Wa and Ha.

[0087] Animal Description: Charles River athymic nude (Nu/Nu) mice (male) were purchased from Charles River Laboratories. Animals were allowed 5 days to acclimate before commencement of the study. Animals were weighed one day prior to injection. Starting body weights were between 20 and 25 grams. Animals were ear punched for identification and housed 5 per cage until randomization by tumor size. Once animals were assigned to groups, they were housed 1 per cage.

[0088] Enzyme Solutions: Compositions of pEPO enzyme solution and activator solution (peroxide) were prepared. The enzyme solution contained a final concentration of pEPO of 2.5µg/ml, (0.8-0.05mM each L-alanine, L-proline, glycine, final concentration), ethanolamine (2.4-0.15mM, final concentration), sodium bromide (2mM) and Tween-80 (0.1%, v/v). The activator solution comprised hydrogen peroxide at 0.003%, v/v, 890µM in phosphate-buffered saline (PBS) pH 7.4. The vehicle was PBS.

[0089] Fifteen microliters of activator solution was added to vehicle or enzyme solution and allowed to incubate for ~3-5 minutes prior to dosing. Dosing solutions were activated for each individual animal. Following activation, ~1 ml of dosing solution was injected into the surgical cavity. The cavity was filled to completion until some leaking of fluid from the surgical site was observed.

Experimental Design

[0090] HT-1080 cells fibrosarcoma cells were cultured and expanded under routine conditions noted above. On the day of injection into mice, cells were harvested, washed with phosphate buffered saline, and resuspended at a concentration 5×10^7 cells/ml. Thirteen athymic nude mice (13 males) were injected SC in the right flank with HT1080 cells (concentration 5.1×10^6 cells/animal, volume 100 µl/animal). Following injection, animals were weighed weekly and monitored for tumor formation. Tumors were measured twice a week using external calipers once tumors were visible and had reached a measurable size.

[0091] When tumors reached 0.5-1 cm³, animals were randomized into two groups of 5 mice. The tumors were surgically removed from both groups. Surgical wounds were sealed after excision of the tumor with surgical glue and then the cavity was filled with dosing solution (~1 ml/animal). Group 1 received vehicle + activator while Group 2 received of pEPO + activator. Animals were individually housed following surgery. One

animal from Group 1 (vehicle + activator) was found dead on the day after surgery. This animal was replaced with an extra tumor bearing animal. The tumor was removed from the replacement animal, the surgical wound sealed and the cavity was treated with 1 ml of vehicle + activator.

[0092] After treatment, mortality checks and clinical observation were performed daily. Animals were weighed weekly and on the day of termination. Tumor formation was monitored in animals and when applicable, tumors were measured twice a week using external calipers after tumors had reached a measurable size.

[0093] At the end of 4 weeks, animals were euthanized by carbon dioxide followed by cervical dislocation. Tumors were measured with calipers prior to termination. Following termination, tumors were excised, weighed and fixed in 10% neutral buffered formalin.

Results and Conclusion: *In vivo* Tumor Reduction Activity of pEPO

Tumor growth and clinical observations are noted in Table 1.

Animal ID (tag)	Sex	Finding	Study Day of Finding
Group 1: Vehicle plus Activator			
G1M1	M	No abnormal findings noted	1-53
G1M2	M	No abnormal findings noted	1-29
		Tumor regrowth confirmed	30-39
		Euthanized due to excess tumor size, tumor collected	39
G1M3	M	No abnormal findings noted	1-15, 22-34,
		Redness on top of tumor	16-21
		Slight necrosis on tumor. Trimmed at tumor removal.	21
		Tumor regrowth confirmed	35-43
		Euthanized due to excess tumor size, tumor collected	43
G1M4	M	No abnormal findings noted	1-21
		Found dead (replaced with animal G1M4A)	22
G1M4A	M	No abnormal findings noted	1-53
G1M5	M	No abnormal findings noted	1-29
		Tumor regrowth confirmed	30-53
Group 2: Enzyme plus Activator			
G2M1	M	No abnormal findings noted	1-27, 29-53
		Open wound (closed with wound clip)	28
G2M2	M	No abnormal findings noted	1-29
		Tumor regrowth	30-53
G2M3	M	No abnormal findings noted	1-53
G2M4	M	No abnormal findings noted	1-53
G2M5	M	No abnormal findings noted	1-53

Findings exclude the observations of tumor formation prior to surgical removal and treatment

[0094] Animals injected with HT-1080 cells developed visible tumors by day 11. Tumor masses increased over time and tumors were surgically removed on study day 21 once tumors had reached an average volume of $\sim 0.3 \text{ cm}^3$ with individual tumors reaching $>0.5 \text{ cm}^3$ in some animals.

[0095] Following tumor removal and treatment, 3 of 5 animals in group 1 (vehicle + activator) had tumor re-growth, although the tumor failed to develop extensively in animal G1M5. Only 1 of 5 animals in group 2 (enzyme + activator) had confirmed tumor re-growth. Animals G1M2 and G1M3 were terminated on study 39 and 43 respectively due to complications arising from the presence of the tumor (difficulty moving, lack of visible eating, lack of feces, overall lethargy). Remaining animals were euthanized on study day 53.

[0096] One animal died during the course of this study. Animal G1M4 was found dead on the day after tumor removal surgery and treatment with vehicle + activator. This animal was replaced with one of the remaining tumor bearing animals and treated with vehicle + activator (G1M4a).

[0097] Aside from the presence of the tumor, other clinical observations were minor in nature for study animals. IN addition, no clear differences in body weight were noted on the day of study termination between the two groups.

[0098] Accordingly, this experiment showed that treatment of tumor cavities with activated pEPO resulted in a decreased number of animals showing tumor regrowth (1 of 5) versus 3 of 5 animals receiving vehicle + activator.

Example 2 - Refined assessment of the *in vivo* tumor reduction activity of pEPO

[0099] A similar protocol as described in Example 1 was followed, but with slight variations. Specifically, a larger cohort of thirty-eight athymic nude mice (38 males) were injected SC in the right flank with HT-1080 cells (same concentration as used in Example 1 of 5.0×10^6 cells/animal, volume 100 μl /animal). Following injection, animals were weighed weekly and monitored for tumor formation. Tumors were measured twice a week using external calipers once tumors were visible and had reached a measurable size.

[0100] Whereas in Example 1 tumors were allowed to reach $0.5\text{-}1 \text{ cm}^3$, in this further example, tumors were allowed to reach 0.1 to 0.3 cm^3 . Animals were then randomized into two groups of 15 mice. The tumors were surgically removed from both groups. Surgical wounds were sealed after excision of the tumor with surgical glue and then the cavity was filled with dosing solution ($\sim 1 \text{ ml}$ /animal). Group 1 received phosphate buffered

saline while Group 2 received of pEPO activator. Animals were individually housed following surgery. Procedure according to Example 1 was otherwise followed.

Results and Conclusion: *In vivo* Tumor Reduction Activity of pEPO

Tumor growth and clinical observations from this further example are noted in Table 2.

Animal ID	Finding	Study Day of Finding
Group 1: Phosphate Buffered Saline		
G1M1	No abnormal finding	1-99
G1M2	No abnormal finding	1-42
	Lesion on skin over tumor. Treated with topical antibiotic	43-56
	Euthanized due to tumor size	56
G1M3	No abnormal finding	1-99
G1M4	Lesion on skin over tumor. Treated with topical antibiotic	21-23
G1M5	No abnormal finding	1-99
G1M6	No abnormal finding	1-49
	Lesion on skin over tumor. Treated with topical antibiotic	50-88
	Euthanized due to tumor size	88
G1M7	No abnormal finding	1-27
	Lesion on skin over tumor. Treated with topical antibiotic	28-31
G1M8	No abnormal finding	1-49
	Lesion on skin over tumor. Treated with topical antibiotic	50-62
	Euthanized due to tumor size	63
G1M9	No abnormal finding	1-65
	Lesion on skin over tumor. Treated with topical antibiotic	66-92
	Hunched position. Appears dehydrated and losing weight	91-92
	Euthanized due to moribund status	92
G1M10	No abnormal finding	1-99
G1M11	No abnormal finding	1-99
G1M12	No abnormal finding	1-49
	Lesion on skin over tumor. Treated with topical antibiotic	50-66
	Euthanized due to tumor size	66
G1M13	No abnormal finding	1-99
G1M14	No abnormal finding	1-99
G1M15	No abnormal finding	1-62
	Euthanized due to tumor size	63

Animal ID	Finding	Study Day of Finding
Group 2: Enzyme Plus Activator		
G2M1	No abnormal finding	1-49
	Lesion on skin over tumor. Treated with topical antibiotic	50-90
	Animal appears dehydrated and weak	91-92
	Euthanized due to tumor size	92
G2M2	No abnormal finding	1-20
	Lesion on skin over tumor. Treated with topical antibiotic	21-23
G2M3	No abnormal finding	1-20, 24-88
	Lesion on skin over tumor. Treated with topical antibiotic	21-23
	Euthanized due to tumor size	88
G2M4	No abnormal finding	1-93
	Axillary lymph node swollen	94-99
G2M5	No abnormal finding	1-20
	Lesion on skin over tumor. Treated with topical antibiotic	21-23
G2M6	No abnormal finding	1-99
G2M7	No abnormal finding	1-42
	Lesion on skin over tumor. Treated with topical antibiotic	43-98
	Hunched position. Appears dehydrated and losing weight	98
	Euthanized due to tumor size/moribund status	98
G2M8	No abnormal finding	1-99
G2M9	No abnormal finding	1-27, 32-99
	Lesion on skin over tumor. Treated with topical antibiotic	28-31
G2M10	No abnormal finding	1-7, 14-20, 24-99
	Bite marks on animal. Aggressive cage mate removed	8-13
	Lesion on skin over tumor. Treated with topical antibiotic	21-23
G2M11	No abnormal finding	1-97
	Axillary lymph node swollen	98-99
G2M12	No abnormal finding	1-19, 36-41
	Lesion on skin over tumor. Treated with topical antibiotic	20-35, 42-85
	Euthanized due to tumor size	85
G2M13	No abnormal finding	1-99
G2M14	No abnormal finding	1-30, 32-70
	Opened wound. Closed with clip	31
	Euthanized due to tumor size	70
G2M15	No abnormal finding	1-99

[0101] Animals injected with HT-1080 cells developed visible tumors by day 10. Tumor masses increased over time, and tumors were surgically removed on study day 24 once tumors had reached an average volume of ~0.15 cm³.

[0102] Following tumor removal and treatment of the tumor cavity, tumors redeveloped in 6 of 15 animals from Group 1 (phosphate buffered saline) and 5 of 15 animals from group 2 (enzyme + activator). While the number of animals developing tumors and the time to tumor emergence was similar in both groups, the rate of growth of the tumors in the two groups appeared to be different. Tumors in the Group 1 control animals increased in volume more rapidly than those in the Group 2 enzyme + activator treated animals. On average, tumors in group 2 animals required an additional 15 days to reach a similar size compared to group 1 control tumors.

[0103] A similar result was observed when monitoring survival of animals. Non-survival was defined as the study day for which the tumor reached maximal tumor volume and the animal was euthanized. As with the tumor volumes, the Enzyme/activator treated animals survived longer than the control treated animals.

[0104] Following surgical removal of HT-1080 tumors and treatment of tumor cavities with activated Enzyme solution (porcine eosinophil peroxidase, pEPO) or phosphate buffered saline as a control, 6 of 15 animals from the phosphate buffered saline group and 5 of 15 animals from Enzyme plus activator group developed tumors. Animals in which tumor cavities were treated with activated enzyme solution resulted in slower tumor growth and extended survival relative to the phosphate buffered saline treatment. Results are shown graphically in Figure 1. In Figure 1A, tumor volumes are plotted as a function of post-surgery study day out to study day 42 (the first day any tumor reached the maximum size of 1 cm³). The same data is presented in Figure 1B except that tumor volumes are plotted out to the terminal study day. When calculating average tumor volumes for later study days, the tumor volume obtained at the time of euthanasia for each animal was used for all remaining study days.

[0105] A similar result was observed when monitoring survival of animals. Non-survival was defined as the study day for which the tumor reached maximal tumor volume and the animal was euthanized. Results of the survival study curves are presented in Figure 2. In Figure 2A, a survival curve is shown where percent survival is calculated using all study animals. In Figure 2B, the survival curve is only for the animals that redeveloped tumors. As with the tumor volumes, the enzyme + activator treated animals survived longer than the control treated animals.

Example 3 - *In vitro* activity of porcine myeloperoxidase (pMPO) against bladder cancer cells

[0106] Experiments were performed, as described below, to determine the activity of porcine myeloperoxidase (MPO) against human bladder cancer cell lines (T24 and 5637) and human normal bladder epithelium (SV-HUC-1). The 5637 cell line is a highly invasive bladder surface neoplastic cell line and the T24 cell line is an intermediate invasive, transitional epithelium cell line.

[0107] Cell Lines. Two bladder cancer cell lines, 5637 (ATCC HTB-9) and T24 (ATCC HTB-4), and one normal bladder cell line SV-HUC-1 (ATCC CRL-9520) were used in the experiments.

[0108] Reagents. The following stock solutions were used in the experiment. MPO (2 μ M in water); H₂O₂ (100 mM in water); NaCl (6.2 M in water); glycine (21.5 mM in water) and L-proline (21.5 mM in water).

[0109] Experiment 1. An experiment was performed to assess the *in vitro* cytotoxicity of individual reagents against bladder cancer cell lines and a normal bladder cell line. The individual reagents were myeloperoxidase (MPO), NaCl, glycine, and L-proline.

[0110] Method. The bladder cancer cell lines, 5637 and T24, and normal bladder cell line SV-HUC-1 were revived into the recommended culture media. Twenty-four hours prior to the initiation of the assay, the cell lines were seeded into 96 well plates at 2000 cells/well. Six replicate wells were prepared for each reagent assay. Each cell line was seeded in four 96 well plates to monitor the cell viability for four days. Cells were allowed to recover overnight prior to treatment.

[0111] On the day of treatment, each stock solution was diluted in McCoy's culture media (vehicle) at pH 5.6 to generate the following treatment solutions:

[0112] Assay 1. NaCl at concentrations: 10 mM, 20 mM, 40 mM, 80 mM, 100 mM, 200 mM, 300 mM, 400 mM, 500 mM, and 600 mM.

[0113] Assay 2. MPO at concentrations: 10 mM, 20 mM, 40 mM, 80 mM, 100 mM, 200 mM, 300 mM, 400 mM, 500 mM, and 600 mM.

[0114] Assay 3. Combination of glycine + L-proline at concentrations for each amino acid: 0.21 mM, 0.42 mM, 0.84 mM, 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, and 6 mM and 7 mM.

[0115] For each assay, media was used as a control. Media was removed from the cells and wells. Wells were treated with the individual treatment solutions as indicated above. Treatments were performed for 45 minutes at 37°C, 5%CO₂. Treatment solutions were then removed and replaced with standard culture media. Plates were incubated for 24, 48, or 72 hours after treatment. At each post-treatment time point, Promega CellTiter Aqueous Reagent (an MTS viability reagent) solution was added to each well of the plate and development was performed at 37°C, 5%CO₂. Plates were read hourly for absorbance at 490 nm.

[0116] Results. The data obtained from Experiment 1 showed that each individual reagent, even at higher concentrations, had little or no cytotoxic effect on cancer cells or

normal cells. This result indicates that MPO alone is not cytotoxic against bladder cancer cells.

[0117] Experiment 2. An experiment was performed to assess the *in vitro* cytotoxicity of an MPO composition against bladder cancer cell lines and a normal bladder cell line. The composition comprised MPO, H₂O₂, NaCl, glycine, and L-proline at various concentrations.

[0118] Method: The cell lines used were as described in Experiment 1. Twenty-four hours prior to the initiation of the assay, the cell lines were seeded into 96 well plates at 2000 cells/well or 4000 cells/well. Six replicate wells were prepared for each treatment solution (a. - e., as indicated below). Each cell line was seeded in four 96 well plates to monitor the cell viability for four days. Cells were allowed to recover overnight prior to treatment.

[0119] On the day of treatment, each stock solution was diluted in McCoy's culture media at pH 5.6 and then combined to generate the following treatment solutions: Composition A - Medium pH 5.6 (Vehicle); Composition B - Medium pH 5.6 + NaCl (100 mM) + glycine (0.21 mM) + L-proline (0.21 mM) + MPO (20 nM); Composition C - Medium pH 5.6 + NaCl (100 mM) + glycine (0.21 mM) + L-proline (0.21 mM) + H₂O₂ (1 mM); Composition D - Medium pH 5.6 + NaCl (10 mM) + glycine (0.21 mM) + L-proline (0.21 mM) + MPO (20 nM) + H₂O₂ (1 mM); and Composition E - Medium pH 5.6 + NaCl (100 mM) + glycine (0.21 mM) + L-proline (0.21 mM) + MPO (20 nM) + H₂O₂ (1 mM).

[0120] Media was removed from the cells and wells. Treatment solutions were added to the wells, as applicable, and treatments were performed for 45 minutes at 37°C, 5%CO₂. Treatment solutions were then removed and replaced with standard culture media. Plates were incubated for 24, 48, or 72 hours after treatment. At each post-treatment time point, Promega CellTiter Aqueous Reagent (an MTS viability reagent) solution was added to each well of the plate and development was performed at 37°C, 5%CO₂. Plates were read hourly for absorbance at 490 nm.

[0121] Results. The data from Experiment 2 showed that Medium alone (Composition A), and Medium, MPO, NaCl, glycine and L-proline (Composition B) exhibited no cytotoxicity against bladder cancer cells or normal bladder cells. This result is consistent with Experiment 1. Composition C (Medium, H₂O₂, NaCl, glycine, and L-proline) exhibited some cytotoxicity against both bladder cancer cells and normal bladder cells. The greatest cytotoxic effects against both bladder cancer cells and normal bladder

cells were exhibited by Compositions D and E (Medium, MPO, H₂O₂, NaCl, glycine, and L-proline.) However, the cytotoxic effect of the combination was greater against the cancer cells lines and was less so against normal cell lines. These results show that the combination of MPO and H₂O₂ in the presence of chloride has a cytotoxic effect against cancer cells, and is less toxic against normal cells.

[0122] **Experiment 3.** An experiment was performed to assess the *in vitro* cytotoxicity of an MPO composition against bladder cancer cell lines and a normal bladder cell line at various cell densities. The composition comprised MPO (1 nM), H₂O₂ (1 mM), NaCl (100 mM), glycine (0.21 mM), and L-proline (0.21 mM).

[0123] **Method:** The cell lines used were as described in Experiment 1. Twenty-four hours prior to the initiation of the assay, the cell lines were seeded into 96 well plates at various cell densities. The bladder cancer cell densities tested were: 15,000 cells/well; 30,000 cells/well; 60,000 cells/well; 90,000 cells/well; 120,000 cells/well; and 400,000 cells/well. The normal bladder cell densities tested were: 4,000 cells/well; 15,000 cells/well; 30,000 cells/well; 60,000 cells/well; 90,000 cells/well; and 120,000 cells/well. Triplicate wells were prepared for each treatment solution. Each cell line was seeded in four 96 well plates to monitor the cell viability for four days. Cells were allowed to recover overnight prior to treatment.

[0124] On the day of treatment, each stock solution was diluted in McCoy's culture media at pH 5.6 and then combined to generate the following treatment solutions: Composition A - Medium pH 5.6 (Vehicle); Composition B - Medium pH 5.6 + NaCl (100 mM) + Glycine (0.21 mM) + L-Proline (0.21 mM) + H₂O₂ (1 mM); and Composition C - Medium pH 5.6 + NaCl (100 mM) + Glycine (0.21 mM) + L-Proline (0.21 mM) + MPO (1 nM) + H₂O₂ (1 mM).

[0125] Media was removed from the cells and wells. Treatment solutions were added to the wells, as applicable, and treatments were performed for 45 minutes at 37°C, 5%CO₂. Treatment solutions were then removed and replaced with standard culture media. Plates were incubated for 72 hours after treatment. Promega CellTiter Aqueous Reagent (an MTS viability reagent) solution was added to each well of the plate and development was performed at 37°C, 5%CO₂. Plates were read hourly for absorbance at 490 nm.

[0126] **Results.** The data from Experiment 3 showed that at the concentrations of MPO (1 nM) and H₂O₂ (1 mM) tested, as the cell density increased, the cytotoxic effect of the MPO composition progressively decreased against both cancer and normal cells.

[0127] **Experiment 4.** An experiment was performed to assess the *in vitro* cytotoxicity of an MPO composition against bladder cancer cell lines and a normal bladder cell line at high cell densities and higher concentrations of MPO (≥ 20 nM) and H₂O₂ (10 mM). The MPO compositions also comprised NaCl (100 mM), glycine (0.21 mM), and L-proline (0.21 mM).

[0128] **Method:** The cell lines used were as described in Experiment 1. Twenty-four hours prior to the initiation of the assay, the cell lines were seeded into 96 well plates at various cell densities. The bladder cancer cell densities tested were: 120,000 cells/well and 400,000 cells/well. The normal bladder cell densities tested were: 50,000 cells/well and 100,000 cells/well. Six replicate wells were prepared for each treatment solution. Each cell line was seeded in four 96 well plates to monitor the cell viability for four days. Cells were allowed to recover overnight prior to treatment.

[0129] On the day of treatment, each stock solution was diluted in McCoy's culture media at pH 5.6 and then combined to generate the following treatment solutions: Composition A - Medium pH 5.6 (Vehicle); Composition B - Medium pH 5.6 + NaCl (100 mM) + glycine (0.21 mM) + L-proline (0.21 mM) + MPO (20 nM) + H₂O₂ (10 mM); and Compositions C - J, which comprised the same concentrations of NaCl (100 mM), glycine (0.21 mM), L-proline (0.21 mM), and H₂O₂ (10 mM). The concentrations of MPO were 40 nM, 80 nM, 100 nM, 120 nM, 140 nM, 160 nM, 180 nM, and 200 nM, respectively.

[0130] Media was removed from the cells and wells. Treatment solutions were added to the wells, as applicable, and treatments were performed for 45 minutes at 37°C, 5%CO₂. Treatment solutions were then removed and replaced with standard culture media. Plates were incubated for 72 hours after treatment. Promega CellTiter Aqueous Reagent (an MTS viability reagent) solution was added to each well of the plate and development was performed at 37°C, 5%CO₂. Plates were read hourly for absorbance at 490 nm.

[0131] **Results.** The data from Experiment 4 showed that the concentrations of MPO (≥ 20 nM) and H₂O₂ (10 mM) tested, at higher cell densities, resulted in the highly selective killing of human bladder cancer cells with the sparing of normal human bladder cells.

Example 4 - *In vitro* activity of porcine eosinophil peroxidase (pEPO) against bladder cancer cells

[0132] Experiments are planned to determine the *in vitro* activity of porcine eosinophil peroxidase (pEPO) against mouse bladder cancer cells. The effect of pEPO on normal bladder cells will also be studied. Stock and diluted solutions will be prepared of EPO,

hydrogen peroxide, sodium bromide, and ethanolamine. The bladder cancer cell line T24 will be treated in the experiment, as will the benign bladder cell line SV-HUC1 as a control. The cells will be treated with the following solutions: (1) cell culture medium ("medium"); (2) medium + hydrogen peroxide (H_2O_2); (3) medium + sodium bromide (NaBr); (4) medium + pEPO; (5) medium + ethanolamine; (6) medium + H_2O_2 + NaBr + ethanolamine; (7) medium + H_2O_2 + EPO + ethanolamine; (8) medium + NaBr + pEPO + ethanolamine; (9) medium + H_2O_2 + NaBr + pEPO; (10) medium + H_2O_2 + NaBr + pEPO + ethanolamine. Both cell lines will be exposed to each of the various treatment solutions for 15 minutes, 30 minutes, and 45 minutes. Cell growth will be measured after treatment at 0 hours, 24 hours, 48 hours, and 72 hours.

Example 5 - *In vivo* bladder tumor reduction activity of porcine eosinophil peroxidase (pEPO)

[0133] Experiments are planned to determine the bladder tumor reduction activity of porcine eosinophil peroxidase (pEPO) in a mouse bladder cancer model in which bladder cancer cells are grown in the bladder of a mouse. A treatment solution comprising eosinophil peroxidase, sodium bromide, and ethanolamine will be mixed with an activator solution comprising hydrogen peroxide in phosphate buffered saline and allowed to activate for three to five minutes. Following activation, the enzyme solution will be applied intravesically through a catheter into the bladder. The reduction in tumor growth will be measured over time.

Example 6 - Treatment of bladder cancer

[0134] Treatment of a patient suffering from bladder cancer is envisaged and may encompass one or more of the following:

- Maintenance of optimal pH of about 5.0 to 6.5 in the bladder environment by lavage.
- Removal of mucosa lining the bladder with dimethyl sulfoxide (DMSO) (optional).
- Pre-mixing a composition comprising myeloperoxidase, sodium chloride, glycine, and L-proline with a solution of hydrogen peroxide to produce a treatment solution.
- Allowing the treatment solution to incubate for three to five minutes.
- Direct instillation/administration of the treatment solution, via urinary catheter, into the bladder.

Example 7- Treatment of bladder cancer

[0135] Phase 1 human clinical trials are planned to treat a patient suffering from bladder cancer and may encompass one or more of the following:

- Maintenance of optimal pH of about 5.0 to 6.5 in the bladder environment by lavage.
- Removal of mucosa lining the bladder with dimethyl sulfoxide (DMSO) (optional).
- A suitable bladder wash with a neutral ionic strength solution, such as Ringers Lactate, which can be applied without stopping the metabolism of the target cancer cell.
- Pre-mixing a composition comprising myeloperoxidase (20 nM - 100 nM), sodium chloride (100 mM), glycine (0.21 mM), and L-proline (0.21 mM) with a solution of hydrogen peroxide (10 mM - 100 mM) to produce a treatment solution.
- Allowing the treatment solution to incubate for three to five minutes.
- Direct instillation/administration of the treatment solution, via urinary catheter, into the bladder.

Example 8- Treatment of bladder cancer

[0136] Phase 1 human clinical trials are planned to treat a patient suffering from bladder cancer and may encompass one or more of the following:

- Maintenance of optimal pH of about 5.0 to 6.5 in the bladder environment by lavage.
- Removal of mucosa lining the bladder with dimethyl sulfoxide (DMSO) (optional).
- A suitable bladder wash with a neutral ionic strength solution, such as Ringers Lactate, which can be applied without stopping the metabolism of the target cancer cell.
- Pre-mixing a composition comprising myeloperoxidase (20 nM - 100 nM), sodium chloride (100 mM), glycine (0.21 mM), and L-proline (0.21 mM).
- Direct instillation/administration of the composition, via urinary catheter, into the bladder.
- Allowing the composition to dwell in the bladder for about ten minutes.
- Direct instillation/administration of hydrogen peroxide (10 mM - 100mM), via urinary catheter, into the bladder to activate the myeloperoxidase composition.

Example 9 - Treatment of bladder cancer

[0137] Treatment of a patient suffering from bladder cancer is envisaged and may encompass one or more of the following:

- Maintenance of optimal pH of about 5.0 to 6.5 in the bladder environment by lavage.
- Removal of mucosa lining the bladder with dimethyl sulfoxide (DMSO) (optional).
- A suitable bladder wash with a neutral ionic strength solution, such as Ringers Lactate, which can be applied without stopping the metabolism of the target cancer cell.
- Direct instillation/administration of compositions comprising a haloperoxidase, a halide, for example bromide or chloride, a peroxide, or peroxide-producing oxidase and a substrate for the oxidase, via urinary catheter.

Example 10 - Treatment of bladder cancer

[0138] Treatment of a patient suffering from bladder cancer is envisaged and may encompass one or more of the following:

- Maintenance of optimal pH of about 5.0 to 6.5 in the bladder environment by lavage.
- Removal of mucosa lining the bladder with dimethyl sulfoxide (DMSO) (optional).
- A suitable bladder wash with a neutral ionic strength solution, such as Ringers Lactate, which can be applied without stopping the metabolism of the target cancer cell.
- Pre-mixing a composition comprising eosinophil peroxidase, sodium bromide, and ethanolamine with a solution of hydrogen peroxide to produce a treatment solution.
- Allowing the treatment solution to incubate for three to five minutes.
- Direct instillation/administration of the treatment solution, via urinary catheter, into the bladder.

Example 11 - Treatment of bladder cancer

[0139] Treatment of a patient suffering from bladder cancer is envisaged and may encompass one or more of the following:

- Maintenance of optimal pH of about 5.0 to 6.5 in the bladder environment by lavage.
- Removal of mucosa lining the bladder with dimethyl sulfoxide (DMSO) (optional).

- A suitable bladder wash with a neutral ionic strength solution, such as Ringers Lactate, which can be applied without stopping the metabolism of the target cancer cell.
- Pre-mixing a composition comprising eosinophil peroxidase, sodium bromide and ethanolamine.
- Direct instillation/administration of the composition, via urinary catheter, into the bladder.
- Allowing the composition to dwell in the bladder for about ten minutes.
- Direct instillation/administration of hydrogen peroxide, via urinary catheter, into the bladder to activate the myeloperoxidase composition.

[0140] While illustrative embodiments have been illustrated and described, including the best mode known to the inventors for carrying out the invention, those skilled in the art will recognize that the disclosure may be practiced with variations on the disclosed structures, materials, compositions and methods, and such variations are regarded as within the ambit of the disclosure.

[0141] Discussion or mention of any piece of prior art in this specification is not to be taken as an admission that the prior art is part of the common general knowledge of the skilled addressee of the specification.

[0142] The contents of all references, and published patents and patent applications cited throughout the application are hereby incorporated by reference.


CLAIMS

1. A method of treating a solid cancer in a patient, the method comprising: administering an effective amount of a pharmaceutical composition comprising myeloperoxidase, hydrogen peroxide or a source of hydrogen peroxide, and halide to the patient.
2. The method of Claim 1, wherein the source of hydrogen peroxide is a peroxide-producing oxidase that produces hydrogen peroxide in the presence of a substrate for the oxidase.
3. The method of Claim 2, wherein the peroxide-producing oxidase is glucose oxidase and the substrate is glucose.
4. The method of Claim 1, wherein the halide is sodium chloride.
5. The method of Claim 1, wherein the composition further comprises one or more amino acids.
6. The method of Claim 5, wherein the one or more amino acids is selected from the group comprising glycine, L-alanine, D-alanine, L-alanine anhydride, L-glutamine, L-glutamic acid, glycine anhydride, hippuric acid, L-histidine, L-leucine, D-leucine, L-isoleucine, D-isoleucine, L-lysine, L-ornithine, D-phenylalanine, L-phenylalanine, L-proline, L-hydroxyproline, L-serine, L-taurine, L-threonine, D-threonine, L-tyrosine, L-valine, D-valine, beta amino acids, such as beta alanine, L-beta-homoleucine, D-beta-homoleucine, 3-aminobutanoic acid, L-2,3-diaminopropionic acid monohydrochloride, D-2,3-diaminopropionic acid monohydrochloride, L-3-aminoisobutyric acid, D-3-aminoisobutyric acid, ethyl 3-aminobutyrate, sarcosine methyl ester hydrochloride and nipecotic acid, or an alkyl ester or pharmaceutically acceptable salt thereof.
7. The method of Claim 6, wherein the amino acids are glycine and L-proline.
8. The method of Claim 1, wherein the solid cancer is selected from the group comprising: breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, cervical cancer, kidney and renal pelvis cancer, endometrial cancer, pancreatic cancer, thyroid cancer, liver cancer, brain cancer and spinal cord cancer.
9. The method of Claim 8, wherein the solid cancer is bladder cancer.

10. A method of treating a solid cancer in a patient, the method comprising: administering an effective amount of a pharmaceutical composition comprising myeloperoxidase, sodium chloride, glycine, L-proline, and hydrogen peroxide.
11. The method of Claim 1, wherein the pharmaceutical composition is comprised of (a) a first composition comprising myeloperoxidase, a halide, and amino acids; and (b) a second composition comprising a peroxide.
12. The method of Claim 11, wherein the first composition and the second composition are premixed before administration.
13. The method of Claim 11, wherein the first composition and the second composition are administered concurrently or sequentially.
14. A method of treating bladder cancer in a patient, the method comprising the steps of: maintaining a pH of about 5.0 to 6.5 in the bladder environment by lavage; applying a suitable bladder wash solution having a neutral ionic strength; pre-mixing a composition comprising myeloperoxidase, sodium chloride, glycine, and L-proline with a solution of hydrogen peroxide to produce a treatment solution; allowing the treatment solution to incubate for three to five minutes; instilling the treatment solution, via urinary catheter, into the bladder.
15. The method of Claim 12, wherein the treatment solution comprises myeloperoxidase in a concentration 20 nM - 100 nM, sodium chloride in a concentration of 100 mM, glycine in a concentration of 0.21 mM, L-proline in a concentration of 0.21 mM and hydrogen peroxide in a concentration of 10 mM - 100 mM.
16. A method of treating bladder cancer in a patient, the method comprising the steps of: maintaining a pH of about 5.0 to 6.5 in the bladder environment by lavage; applying a suitable bladder wash solution having a neutral ionic strength; pre-mixing a composition comprising myeloperoxidase, sodium chloride, glycine, and L-proline; instilling the composition, via urinary catheter, into the bladder; allowing the composition to dwell in the bladder for about ten minutes; and instilling hydrogen peroxide, via urinary catheter, into the bladder to activate the myeloperoxidase composition.
17. The method of Claim 16, wherein the composition comprises myeloperoxidase in a concentration 20 nM - 100 nM, sodium chloride in a concentration of 100 mM, glycine in a concentration of 0.21 mM, and L-proline in a concentration of 0.21 mM.

18. The method of Claim 16, wherein the concentration of the hydrogen peroxide is from 10 mM - 100 mM.
19. A pharmaceutical composition for treating a solid cancer in a patient, the composition comprising myeloperoxidase, a halide, and hydrogen peroxide.
20. The pharmaceutical composition of Claim 19, further comprising one or more amino acids.
21. A pharmaceutical composition for treating bladder cancer in a patient, the composition comprising myeloperoxidase, sodium chloride, glycine, L-proline, hydrogen peroxide, and a pharmaceutically acceptable carrier.
22. A pharmaceutical composition for treating bladder cancer in a patient, the composition comprising myeloperoxidase, sodium chloride, glycine, L-proline, glucose oxidase, glucose, and a pharmaceutically acceptable carrier.

A



B





Figure 1

2/2

A



B




Figure 2

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 23/18289

A. CLASSIFICATION OF SUBJECT MATTER
 IPC - INV. A61P 35/00, A61K 47/02, A61K 47/18 (2023.01)
 ADD. A61K 38/00 (2023.01)

CPC - INV. A61P 35/00, A61K 47/02, A61K 47/183

ADD. A61K 38/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) *

See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

See Search History document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4486408 A (Kiel et al.) 04 December 1984 (04.12.1984) col7, ln22-23; claims 38, 41, 44	1-3, 8-9
Y		4-7, 10-13
Y	US 2014/0120076 A1 (Exoxemis, Inc.) 01 May 2014 (01.05.2014) para [0010], [0082], [0125]	4-7, 10-18
Y	WO 2021/202592 A2 (Oregon Health & Science University) 07 October 2021 (07.10.2021) para [0104], [0125]-[0126], [0132]	10-18
A	WO 1990/03185 A1 (Ideon Corporation) 05 April 1990 (05.04.1990) abstract	1-18
A	WO 2007/103525 A2 (Glanbia Nutritionals (Ireland) Limited) 13 September 2007 (13.09.2007) para [0008]	1-18
X/P	WO 2022/103515 A1 (Exoxemis, Inc.) 19 May 2022 (19.05.2022) abstract	1
X/P	Ralph et al. Intratumoral pro-oxidants promote cancer immunotherapy by recruiting and reprogramming neutrophils to eliminate tumors, Cancer Immunology, Immunotherapy (2023) 72:527-542, published online 17 August 2022	1

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"D" document cited by the applicant in the international application

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

15 June 2023 (15.06.2023)

Date of mailing of the international search report

SEP 07 2023

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents

P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-8300

Authorized officer

Kari Rodriguez

Telephone No. PCT Helpdesk: 571-272-4300

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 23/18289

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
---see supplemental box---

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-18

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 23/18289

Box III: lack of unity

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I: Claims 1-18, directed to a method of treating a solid cancer in a patient, the method comprising: administering an effective amount of a pharmaceutical composition comprising myeloperoxidase, hydrogen peroxide or a source of hydrogen peroxide, and halide to the patient.

Group II: Claims 19-22-directed to a pharmaceutical composition for treating a solid cancer in a patient, the composition comprising myeloperoxidase, a halide, and hydrogen peroxide.

The group of inventions listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Special Technical Features:

Group I requires the special technical feature of a method of treating a solid cancer in a patient, the method comprising: administering an effective amount of a pharmaceutical composition comprising myeloperoxidase, hydrogen peroxide or a source of hydrogen peroxide, and halide to the patient, not required by Group II.

Common Technical Features:

Groups I-II share the technical feature of a pharmaceutical composition for treating a solid cancer in a patient, the composition comprising myeloperoxidase, a halide, and hydrogen peroxide.

These shared technical features, however, do not provide a contribution over the prior art, as being anticipated by US 4486408 A to Kiel et al. (hereinafter 'Kiel'). Kiel teaches a pharmaceutical composition comprising myeloperoxidase (claim 41, first enzyme is myeloperoxidase), hydrogen peroxide or a source of hydrogen peroxide (claim 38, enzymes that produce hydrogen peroxide), and halide (claim 38, halide ion).

As the technical features were known in the art at the time of the invention, this cannot be considered a special technical feature that would otherwise unify the groups. Groups I-II therefore lack unity under PCT Rule 13 because they do not share a same or corresponding special technical feature.